|
Press Releases |
|
|
|
Monday, August 17, 2020 |
|
Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment dorzagliatin in China |
Bayer and Hua Medicine, a leading innovative drug development company, today announced a commercialization agreement and strategic partnership for dorzagliatin, a novel diabetes treatment, in China. more info >> |
|
Wednesday, July 1, 2020 |
|
华领医药宣布Dorzagliatin与二甲双胍联合用药III期注册临床研究24周核心研究取得正面结果 |
华领医药今天宣布其在中国开展的全球首创新药葡萄糖激酶激活剂dorzagliatin与二甲双胍(2型糖尿病全球一线用药)联合用药III期注册临床研究(HMM0302)的24周核心研究的正面结果。 more info >> |
|
華領醫藥宣佈Dorzagliatin與二甲雙胍聯合用藥III期註冊臨床研究24週核心研究取得正面結果 |
華領醫藥今天宣佈其在中國開展的全球首創新藥葡萄糖激酶激活劑dorzagliatin與二甲雙胍(2型糖尿病全球一線用藥)聯合用藥III期註冊臨床研究(HMM0302)的24週核心研究的正面結果。 more info >> |
|
Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin |
Hua Medicine today announced the positive 24-week top-line results from HMM0302, a Phase III registration trial in China of its global first-in-class glucokinase activator dorzagliatin add-on to metformin, a first line oral antidiabetic therapy in Type 2 diabetes. more info >> |
|
Thursday, June 18, 2020 |
|
华领医药成功完成Dorzagliatin单药治疗III期临床试验SEED研究(HMM0301) |
华领医药(“公司”,香港联交所股份代号:2552.HK),一家针对全球糖尿病患者尚未满足的临床需求研发全球原创新药的生物技术公司,今天宣布了dorzagliatin的首个III期临床试验,SEED(也称为HMM0301)的结果。 more info >> |
|
華領醫藥成功完成Dorzagliatin單藥治療III期臨床試驗SEED研究(HMM0301) |
華領醫藥(“公司”,香港聯交所股份代號:2552.HK),一家針對全球糖尿病患者尚未滿足的臨床需求研發全球原創新藥的生物技術公司,今天宣佈了dorzagliatin的首個III期臨床試驗,SEED(也稱為HMM0301)的結果。 more info >> |
|
Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin Phase III Monotherapy Trial |
Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced topline results from SEED (also known as HMM0301) more info >> |
|
Monday, April 27, 2020 |
|
华领医药宣布Dorzagliatin与恩格列净(一种SGLT-2抑制剂)联合用药临床研究的成功结果 |
华领医药技术(上海)有限公司(以下简称「华领医药」,香港联交所股份代号:2552.HK)宣布临床研究HMM0112的成功结果。 more info >> |
|
華領醫藥宣佈Dorzagliatin與恩格列淨(一種SGLT-2抑制劑)聯合用藥臨床研究的成功結果 |
華領醫藥技術(上海)有限公司(以下簡稱「華領醫藥」,香港聯交所股份代號:2552.HK)宣佈臨床研究HMM0112的成功結果。 more info >> |
|
Hua Medicine Announces Positive Results in the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor) |
Hua Medicine (the "Company", Stock Code: 2552. HK) today announces the positive results of the clinical study HMM0112. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
乐普生物2023年收入快速增长,亏损大幅收窄,ADC进入收获期
Mar 29, 2024 19:48 HKT/SGT
|
|
|
樂普生物2023年收入快速增長,虧損大幅收窄,ADC進入收穫期
Mar 29, 2024 19:41 HKT/SGT
|
|
|
TANAKA Memorial Foundation Announces Recipients of FY2023 Precious Metals Research Grants
Mar 29, 2024 19:19 HKT/SGT
|
|
|
Guoquan: Continuously Expanding the Business Scale While Enhancing Profitability
Mar 29, 2024 19:02: JST
|
|
|
海通恒信业绩出炉:切实服务实体经济发展 经营质效稳步提升
Mar 29, 2024 18:56 HKT/SGT
|
|
|
海通恒信業績出爐:切實服務實體經濟發展 經營質效穩步提升
Mar 29, 2024 18:52 HKT/SGT
|
|
|
和泓服务:深耕西南区域,业绩稳健增长
Mar 29, 2024 18:43 HKT/SGT
|
|
|
和泓服務:深耕西南區域,業績穩健增長
Mar 29, 2024 18:31 HKT/SGT
|
|
|
MHI Concludes Positive Impact Finance Agreement
Mar 29, 2024 19:20 JST
|
|
|
锅圈:持续扩大业务规模 盈利能力持续增强
Mar 29, 2024 18:10 HKT/SGT
|
|
|
鍋圈:持續擴大業務規模 盈利能力持續增強
Mar 29, 2024 18:07 HKT/SGT
|
|
|
Guoquan: Continuously Expanding the Business Scale While Enhancing Profitability
Mar 29, 2024 18:02 HKT/SGT
|
|
|
Legend Holdings Realized Revenue of RMB436 billion in 2023
Mar 29, 2024 17:55: JST
|
|
|
直面企业发展转型挑战 联想控股如何发展新质生产力
Mar 29, 2024 17:14 HKT/SGT
|
|
|
直面企業發展轉型挑戰 聯想控股如何發展新質生產力
Mar 29, 2024 17:10 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|